Literature DB >> 3322011

Female external genitalia and müllerian duct derivatives in a 46,XY infant with the smith-lemli-Opitz syndrome.

M G Bialer1, V B Penchaszadeh, E Kahn, R Libes, G Krigsman, M L Lesser.   

Abstract

We report on a 46,XY newborn infant with Smith-Lemli-Opitz (SLO) syndrome with female external genitalia, intraabdominal testes with epididymides and deferent ducts and a normally shaped uterus and vagina. Polydactyly, cleft palate, and several internal organ malformations were also present, and the patient died shortly after birth. Data on six reported male infants with SLO syndrome and female external genitalia suggest a correlation between degree of genital involvement and overall degree of severity. Scoring systems to quantify overall degree of severity (SLO score) and degree of genital involvement in males (genital score) were devised and applied to 122 reported cases from the literature. Statistical analyses showed a unimodal distribution of the SLO severity scores, and positive correlations between the SLO score and the genital score in males, the presence of polydactyly, and the presence of cleft palate. In 19 multiplex families the affected sibs were generally similar in their SLO scores. The above analyses suggest that the wide phenotypic variability in the SLO syndrome is determined by variable expressivity of the same entity as opposed to genetic heterogeneity. The observed phenotypic correlations naturally determine that males with complete feminization are among the more severe patients and tend to have polydactyly and cleft palate.

Entities:  

Mesh:

Year:  1987        PMID: 3322011     DOI: 10.1002/ajmg.1320280320

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

Review 2.  Molecular determinants of sexual differentiation.

Authors:  J S Wiener; M Marcelli; D J Lamb
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 3.  The Smith-Lemli-Opitz syndrome.

Authors:  R I Kelley; R C Hennekam
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

4.  Statins for Smith-Lemli-Opitz syndrome.

Authors:  Rami A Ballout; Simona Bianconi; Alicia Livinski; Yi-Ping Fu; Alan T Remaley; Forbes D Porter
Journal:  Cochrane Database Syst Rev       Date:  2020

5.  Spontaneously regressing brain lesions in Smith-Lemli-Opitz syndrome.

Authors:  An N Dang Do; Eva H Baker; Katherine E Warren; Simona E Bianconi; Forbes D Porter
Journal:  Am J Med Genet A       Date:  2017-12-11       Impact factor: 2.802

Review 6.  Smith-Lemli-Opitz syndrome: a treatable inherited error of metabolism causing mental retardation.

Authors:  M J Nowaczyk; D T Whelan; T W Heshka; R E Hill
Journal:  CMAJ       Date:  1999-07-27       Impact factor: 8.262

7.  Corpus callosum measurements correlate with developmental delay in Smith-Lemli-Opitz syndrome.

Authors:  Ryan W Y Lee; Shoko Yoshida; Eun Sol Jung; Susumu Mori; Eva H Baker; Forbes D Porter
Journal:  Pediatr Neurol       Date:  2013-08       Impact factor: 3.372

8.  Assays of plasma dehydrocholesteryl esters and oxysterols from Smith-Lemli-Opitz syndrome patients.

Authors:  Wei Liu; Libin Xu; Connor R Lamberson; Louise S Merkens; Robert D Steiner; Ellen R Elias; Dorothea Haas; Ned A Porter
Journal:  J Lipid Res       Date:  2012-10-16       Impact factor: 5.922

9.  Clinical features and molecular analysis of the alpha thalassemia/mental retardation syndromes. II. Cases without detectable abnormality of the alpha globin complex.

Authors:  A O Wilkie; H C Zeitlin; R H Lindenbaum; V J Buckle; N Fischel-Ghodsian; D H Chui; D Gardner-Medwin; M H MacGillivray; D J Weatherall; D R Higgs
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

10.  Brain magnetic resonance imaging findings in Smith-Lemli-Opitz syndrome.

Authors:  Ryan W Y Lee; Sandra K Conley; Andrea Gropman; Forbes D Porter; Eva H Baker
Journal:  Am J Med Genet A       Date:  2013-08-05       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.